½ÃÀ庸°í¼­
»óǰÄÚµå
1405768

ü¿Ü Æó ¸ðµ¨ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

In Vitro Lung Model Market Size, Share & Trends Analysis Report By Type (2D Model, 3D Model), By Application (Physiological Research, 3D Model Development), By End-use, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 130 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ü¿Ü Æó ¸ðµ¨ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ Ã¼¿Ü Æó ¸ðµ¨ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 9¾ï 4,810¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2030³âÀÇ CAGRÀº 17.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î´Â µ¿¹° ½ÇÇè ¸ðµ¨À» ´ëüÇÒ ¼ö ÀÖ´Â ´ë¾È¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, ÃÖ±Ù ¼ö³â°£ Àü ¼¼°è¿¡¼­ È£Èí±â °ü·Ã ÁúȯÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡À» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. ½ÃÇè°ü³» Æó ¸ðµ¨Àº ¿¬±¸ÀÚµéÀÌ Æ¯Á¤ È£Èí±â ÁúȯÀ» ÀçÇöÇϰí ÀáÀçÀûÀÎ Ä¡·á ¿É¼Ç °³¹ßÀ» À§ÇØ ÀÌ·¯ÇÑ ÁúȯÀÇ ¼¼Æ÷ ¹× ºÐÀÚ Æ¯¼ºÀ» ¹ÐÁ¢ÇÏ°Ô ¸ð¹æÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´ ¸ðµ¨¸µÀº ½ÃÇè°ü³» Æó ¸ðµ¨ÀÇ Àü¹ÝÀûÀÎ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹µ¿¹°º¸È£Çùȸ(HSUS)ÀÇ º¸°í¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¸Å³â ¾à 5,000¸¸ ¸¶¸®ÀÇ µ¿¹°ÀÌ ½ÇÇè¿¡ »ç¿ëµË´Ï´Ù. µ¿¹°¿¡ ´ëÇÑ ÀÜÀÎÇÑ ÇàÀ§¸¦ ÁÙÀ̱â À§ÇØ µ¿¹°º¹Áö¹ý(AWA)Àº µ¿¹°¿¡ ´ëÇÑ À¯ÇØÇÑ ½ÇÇèÀ» ÁÙÀ̱â À§ÇÑ ±ÔÁ¤À» ¸¶·ÃÇϰí ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ ÀÌÀ¯·Î ÃÖ±Ù ¼ö³â°£ ¿¬±¸ ºÐ¾ß¿¡¼­ µ¿¹°ÀÇ À±¸®Àû ó¿ì¿¡ ´ëÇÑ Àü ¼¼°èÀÇ Àνİú °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °­Á¶´Â ½ÃÇè°ü³» Æó ¸ðµ¨¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¿¹°À» ÀÌ¿ëÇÑ À¯Áö ¹× ½ÃÇèÀº ºñ¿ëÀÌ ¸¹ÀÌ µéÁö¸¸, ü¿Ü ¸ðµ¨À» »ç¿ëÇÏ¸é Æ¯È÷ È­ÇÕ¹° ¹× È­Çй°ÁúÀÇ °í󸮷® ½ºÅ©¸®´×¿¡ ÀÖÀ¸¸ç, ºñ¿ë È¿À²¼ºÀÌ ³ô½À´Ï´Ù. ÀÌ·¯ÇÑ ºñ¿ë È¿À²¼ºÀº ¿¹»êÀÌ ÇÑÁ¤µÈ ¿¬±¸ÀÚ³ª Á¶Á÷¿¡°Ô ¸Å·ÂÀûÀ̸ç, ü¿Ü ¸ðµ¨À» µ¿¹° ½ÇÇèÀÇ ½Å·ÚÇÒ ¼ö ÀÖ´Â ´ë¾ÈÀ¸·Î ¸¸µé°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÁøÃâ±â¾÷Àº ÆÄÆ®³Ê½Ê, ÀμöÇÕº´, °è¾à, Á¦Ç° ¹ßÇ¥ µî ´Ù¾çÇÑ Àü·«À» ÅëÇØ ¼¼°è ½ÃÀå Á¡À¯À²°ú Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 6¿ù, AlveoliX´Â Çõ½ÅÀûÀÎ 3D ±¸Á¶ ±â´ÉÀ» Æ÷ÇÔÇÑ »õ·Î¿î Àå±â ¿ÂĨ ½Ã½ºÅÛÀ» ¹ßÇ¥ÇÏ¿© ¸ðµç Àå±âÀÇ ¸ð¹æÀ» ´õ¿í Æí¸®ÇÏ°Ô ¸¸µé¾ú½À´Ï´Ù.

ü¿Ü Æó ¸ðµ¨ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • Æí¸®¼º, È¿À²¼º, Á¾ÇÕÀûÀΠƯ¼ºÀ¸·Î ÀÎÇØ 2D ¸ðµ¨ À¯ÇüÀÌ 2023³â ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀÔ´Ï´Ù.
  • ½Å¾à °³¹ß ¹× µ¶¼º ¿¬±¸ ¿ëµµ´Â ÀǾàǰ ¿¬±¸°³¹ßÀÇ Ãʱ⠴ܰ迡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ 2023³â ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â ÀǾàǰ °³¹ß ¹× ¿¬±¸¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÌ 2023³â ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
  • ºÏ¹Ì´Â ÁÖ¿ä ±â¾÷ ¹× Çмú¿¬±¸ ±â°üÀÌ ÀÌ Áö¿ª¿¡ Á¸ÀçÇϱ⠶§¹®¿¡ 2023³â ¾÷°è¸¦ Áö¹èÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù.
  • ÀÌ ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷Àº ½ÃÀå ÁöÀ§¸¦ À¯ÁöÇϱâ À§ÇØ Á¦Ç° Ãâ½Ã, Á¦ÈÞ ¹× Áö¿ªÀû È®Àå¿¡ Áö¼ÓÀûÀ¸·Î ÁýÁßÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • ¸ð½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ¾÷°è ºÐ¼® Åø
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • COVID-19 °¨¿°ÁõÀÇ ¿µÇ⠺м®

Á¦4Àå À¯Çü ºñÁî´Ï½º ºÐ¼®

  • ü¿Ü Æó ¸ðµ¨ ½ÃÀå : Á¦Ç°ÀÇ º¯µ¿ ºÐ¼®
  • 2D ¸ðµ¨
    • 2D ¸ðµ¨ ½ÃÀå, 2018-2030³â
  • 3D ¸ðµ¨
    • 3D ¸ðµ¨ ½ÃÀå, 2018-2030³â

Á¦5Àå ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ü¿Ü Æó ¸ðµ¨ ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®
  • Drug Discovery¡¤µ¶¼º ¿¬±¸
    • Drug Discovery¡¤µ¶¼º ¿¬±¸ ½ÃÀå, 2018-2030³â
  • »ý¸®ÇÐÀû Á¶»ç
    • »ý¸®ÇÐÀû Á¶»ç ½ÃÀå, 2018-2030³â
  • 3D ¸ðµ¨ °³¹ß
    • 3D ¸ðµ¨ °³¹ß ½ÃÀå, 2018-2030³â
  • ±âŸ
    • ±âŸ ½ÃÀå, 2018-2030³â

Á¦6Àå ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ü¿Ü Æó ¸ðµ¨ ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • Çмú¿¬±¸±â°ü
    • Çмú¿¬±¸±â°ü ½ÃÀå, 2018-2030³â
  • Á¦¾àȸ»ç¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ȸ»ç
    • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ½ÃÀå, 2018-2030³â
  • ±âŸ
    • ±âŸ ½ÃÀå, 2018-2030³â

Á¦7Àå Áö¿ª ºñÁî´Ï½º ºÐ¼®

  • Áö¿ªº° ü¿Ü Æó ¸ðµ¨ ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
  • ºÏ¹Ì
    • ºÏ¹ÌÀÇ Ã¼¿Ü Æó ¸ðµ¨ ½ÃÀå, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ÀÇ Ã¼¿Ü Æó ¸ðµ¨ ½ÃÀå, 2018-2030³â
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ã¼¿Ü Æó ¸ðµ¨ ½ÃÀå, 2018-2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ Ã¼¿Ü Æó ¸ðµ¨ ½ÃÀå, 2018-2030³â
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ã¼¿Ü Æó ¸ðµ¨ ½ÃÀå, 2018-2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ÀÇ ½ÃÀå ÇöȲ ºÐ¼®, 2023³â
  • ±â¾÷ °³¿ä
    • Epithelix
    • MATTEK
    • MIMETAS
    • Lonza
    • Emulate
    • AlveoliX AG
    • InSphero
    • CN Bio Innovations Ltd
    • ATTC Global
    • TissUse GmbH
KSA 24.01.23

In Vitro Lung Model Market Growth & Trends:

The global in vitro lung model market size is expected to reach USD 948.1 million by 2030, growing at a CAGR of 17.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The factors driving market growth include increasing emphasis on creating substitutes for animal testing models, and recent global rise in respiratory-related disorders over the past few years. In vitro lung models help researchers replicate specific respiratory diseases, closely mimicking the cellular and molecular characteristics of these disorders for the development of potential treatment options. Thus, disease modeling contributes to the overall growth of in vitro lung models. Furthermore, as per The Humane Society of the United States (HSUS) report, about 50 million animals are used in experiments each year in the U.S. To mitigate cruelty to animals, the Animal Welfare Act (AWA) has established regulations aimed at reducing harmful experiments on animals.

Thus, over the past few years, there has been a notable global awareness and concern regarding the ethical treatment of animals in the research field. This emphasis has contributed to the increased demand for in vitro lung models worldwide. Furthermore, maintaining and testing on animals is expensive, whereas the use of in vitro models can be more cost-effective, especially for high-throughput screening of compounds and chemicals. This cost-effectiveness is appealing to researchers and organizations with limited budgets, making in vitro models a dependable alternative to animal testing. Key participants are adopting various strategies including partnerships, mergers & acquisitions, agreements, and product launches, to expand their global footprints and product portfolio. For instance, in June 2023, AlveoliX introduced a new organ-on-chip system that includes innovative 3D structure features, making mimicking any organ more convenient.

In Vitro Lung Model Market Report Highlights:

  • 2D model type dominated the market in 2023 due to their convenience, efficiency, and comprehensive nature
  • The drug discovery & toxicology studies application segment dominated the market in 2023 as these models play a pivotal role in the early stages of pharmaceutical research & development
  • Based on end-use, the pharmaceutical & biotechnology companies segment dominated the market in 2023 due to their critical role in drug development & research
  • North America dominated the industry in 2023 owing to the presence of key players as well as academic research institutions in the region
  • Key players operating in the market constantly focus on product launches, partnerships, and geographical expansions to maintain their market position

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Information Analysis
    • 1.2.2. Market Application & Data Visualization
    • 1.2.3. Data Validation & Publishing
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Application & Validation
  • 1.7. Market Model
  • 1.8. Global Market: CAGR Calculation
  • 1.9. Objectives
    • 1.9.1. Objective 1:
    • 1.9.2. Objective 2:

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of respiratory diseases
      • 3.2.1.2. Advancement in cell culture technology
      • 3.2.1.3. Increasing number of research activities being done towards pulmonary drug development
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of skilled professional
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. In Vitro Lung Model Market: Product Movement Analysis
  • 4.2. 2D Model
    • 4.2.1. 2D Model Market, 2018 - 2030 (USD Million)
  • 4.3. 3D Model
    • 4.3.1. 3D Model Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. In Vitro Lung Model Market: Application Movement Analysis
  • 5.2. Drug discovery and Toxicology Studies
    • 5.2.1. Drug discovery and toxicology studies Market, 2018 - 2030 (USD Million)
  • 5.3. Physiological Research
    • 5.3.1. Physiological Research Market, 2018 - 2030 (USD Million)
  • 5.4. 3D Model Development
    • 5.4.1. 3D Model Development Market, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

  • 6.1. In Vitro Lung Model Market: End-use Movement Analysis
  • 6.2. Academic Research Institutes
    • 6.2.1. Academic Research Institutes Market, 2018 - 2030 (USD Million)
  • 6.3. Pharmaceutical and Biotechnology Companies
    • 6.3.1. Pharmaceutical and Biotechnology Companies Market, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. In Vitro Lung Model Market Share By Region, 2023 & 2030
  • 7.2. North America
    • 7.2.1. North America In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. U.S. In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Canada In Vitro Lung Model Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. UK In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Germany In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. France In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Italy In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Spain In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Denmark In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Sweden In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Norway In Vitro Lung Model Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Japan In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. China In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. India In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Australia In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Thailand In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.4.7. South Korea
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. South Korea In Vitro Lung Model Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Brazil In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Mexico In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Argentina In Vitro Lung Model Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. South Africa In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Saudi Arabia In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. UAE In Vitro Lung Model Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Kuwait In Vitro Lung Model Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Epithelix
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. MATTEK
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. MIMETAS
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Lonza
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Emulate
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. AlveoliX AG
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. InSphero
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. CN Bio Innovations Ltd
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. ATTC Global
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. TissUse GmbH
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦